ANTHERA PHARMACEUTICALS 8-K 2012
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 1, 2012
ANTHERA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (510) 856-5600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
(d) On March 1, 2012, the Board of Directors (the Board) of Anthera Pharmaceuticals, Inc. (the Company), on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Bogdan Dziurzynski to serve on the Board as a Class II director.
Bogdan Dziurzynski, D.P.A. has been a consultant in strategic regulatory management to the biotechnology industry since 2001. Dr. Dziurzynski serves on the Board of the Biologics Consulting Group and the Board of Directors of Dendreon Corporation, a biotechnology company. Dr. Dziurzynski is a fellow, past chairman of the board and a past president of the Regulatory Affairs Professional Society. He also serves as an advisory board member of Integrated Biotherapeutics, Inc. From 1994 to 2001, Dr. Dziurzynski was the Senior Vice President of Regulatory Affairs and Quality Assurance for MedImmune, Inc., a biotechnology company. From 1988 to 1994, Dr. Dziurzynski was Vice President of Regulatory Affairs and Quality Assurance for Immunex Corporation, a biotechnology company. Dr. Dziurzynski has a B.A. in Psychology from Rutgers University, an M.B.A. from Seattle University and a Doctorate in Public Administration from the University of Southern California.
A copy of the press release announcing Dr. Dziurzynski appointment is filed herewith as Exhibit 99.1
(e) In addition, on March 1, 2012, effective April 1, 2012, the Companys Board, upon the recommendation of the Compensation Committee of the Board, approved annual base salary adjustments for certain of the Companys employees, including certain of the Companys named executive officers as part of its annual review of compensation. The adjusted salaries for such named executive officers are as follows:
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.